Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Capital Expenditures (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Capital Expenditures data on record, last reported at $24000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures changed N/A year-over-year to $24000.0; the TTM value through Dec 2025 reached $111000.0, down 8.26%, while the annual FY2025 figure was $111000.0, 8.26% down from the prior year.
  • Capital Expenditures reached $24000.0 in Q4 2025 per ACRS's latest filing, up from $23000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $743000.0 in Q2 2023 and bottomed at -$476000.0 in Q4 2022.
  • Average Capital Expenditures over 5 years is $103500.0, with a median of $49500.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: skyrocketed 337.5% in 2021, then tumbled 1460.0% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $35000.0 in 2021, then crashed by 1460.0% to -$476000.0 in 2022, then skyrocketed by 192.65% to $441000.0 in 2023, then plummeted by 103.17% to -$14000.0 in 2024, then soared by 271.43% to $24000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $24000.0 in Q4 2025, $23000.0 in Q3 2025, and $21000.0 in Q2 2025.